Related references
Note: Only part of the references are listed.Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways
Mohamed W. Attwa et al.
JOURNAL OF SEPARATION SCIENCE (2020)
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
Mohamed W. Attwa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study
Haitham AlRabiah et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
In silicoandin vitrometabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling
Thamer A. Alsubi et al.
RSC ADVANCES (2020)
Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation
Mohamed W. Attwa et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Milind Javle et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Computational methods and tools to predict cytochrome P450 metabolism for drug discovery
Jonathan D. Tyzack et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2019)
Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
Hung Huynh et al.
HEPATOLOGY (2019)
Investigation of metabolic stability of the novel ALK inhibitor brigatinib by Liquid chromatography tandem mass spectrometry
Hany W. Darwish et al.
CLINICA CHIMICA ACTA (2018)
Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS
Mohamed W. Attwa et al.
CLINICA CHIMICA ACTA (2018)
A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate
Mohamed W. Attwa et al.
EUROPEAN JOURNAL OF MASS SPECTROMETRY (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS
Mohamed W. Attwa et al.
CHEMISTRY CENTRAL JOURNAL (2018)
Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Ana Sahores et al.
CURRENT CANCER DRUG TARGETS (2018)
Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
Mohamed W. Attwa et al.
RSC ADVANCES (2018)
Cholangiocarcinoma: Current Knowledge and New Developments
Boris Blechacz
GUT AND LIVER (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation
Sawsan M. Amer et al.
CHEMISTRY CENTRAL JOURNAL (2017)
A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study
Adnan A. Kadi et al.
BIOMEDICAL CHROMATOGRAPHY (2016)
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
William J. Scott et al.
CHEMMEDCHEM (2016)
Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model
Davide Komla-Ebri et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry
Naveen Kadian et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2016)
Rapid validated liquid chromatographic method coupled with Tandem mass spectrometry for quantification of nintedanib in human plasma
Hany W. Darwish et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2016)
Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability
Adnan A. Kadi et al.
PLOS ONE (2016)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Role of Fibroblast Growth Factors in Tumor Growth
M. Korc et al.
CURRENT CANCER DRUG TARGETS (2009)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver
Zoe E. Barter et al.
CURRENT DRUG METABOLISM (2007)
Muscle-invasive urothelial carcinoma of the bladder
S. Bruce Malkowicz et al.
UROLOGY (2007)
Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models
David E. Leahy
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study
JS Park et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas
CW Choi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
Share Paper
